A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
Status:
Active, not recruiting
Trial end date:
2022-05-16
Target enrollment:
Participant gender:
Summary
Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011)
relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible
participants will receive study treatment for 6 months in the Placebo-Controlled Treatment
Period, and then will be eligible to enroll into an 18- month Extension Period during which
all participants will receive sotatercept. All treated patients will be also undergo
follow-up period after last study drug treatment.